Iambic Therapeutics, Inc. (NASDAQ:IAM – Get Free Report)’s stock price traded down 7.1% during trading on Thursday. The company traded as low as $13.56 and last traded at $13.71. Approximately 116,557 shares traded hands during trading, a decline of 83% from the average daily volume of 673,820 shares. The stock had previously closed at $14.76.
Analysts Set New Price Targets
A number of equities research analysts have recently weighed in on IAM shares. Bank of America assumed coverage on Iambic Therapeutics in a research note on Monday, November 9th. They issued a “buy” rating and a $30.00 price objective for the company. Zacks Research began coverage on Iambic Therapeutics in a research note on Tuesday, November 10th. They set a “hold” rating on the stock. Jefferies Financial Group initiated coverage on Iambic Therapeutics in a report on Tuesday, November 10th. They set a “buy” rating and a $35.00 target price for the company. JPMorgan Chase & Co. started coverage on Iambic Therapeutics in a research report on Monday, November 9th. They issued an “overweight” rating and a $22.00 target price for the company. Finally, Citigroup assumed coverage on shares of Iambic Therapeutics in a research report on Monday, November 9th. They set a “buy” rating and a $22.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, Iambic Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $27.25.
Check Out Our Latest Stock Analysis on Iambic Therapeutics
Iambic Therapeutics Trading Down 8.9%
Iambic Therapeutics (NASDAQ:IAM – Get Free Report) last posted its earnings results on Monday, November 16th. The company reported ($6.23) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($5.90). The firm had revenue of $11.35 million during the quarter, compared to analyst estimates of $42.50 million. On average, sell-side analysts expect that Iambic Therapeutics, Inc. will post -1.79 earnings per share for the current fiscal year.
Insider Activity
In related news, Director Evan Lockwood Rachlin bought 718,750 shares of the stock in a transaction on Friday, October 16th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $11,500,000.00. Following the purchase, the director owned 2,588,248 shares of the company’s stock, valued at $41,411,968. This trade represents a 38.45% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 22.90% of the stock is currently owned by corporate insiders.
About Iambic Therapeutics
Iambic Therapeutics is a biotechnology company that uses artificial intelligence and computational methods to discover and develop medicines. Its approach combines machine-learning tools with laboratory research to identify potential drug candidates and guide their design. The company’s pipeline includes IAM1363, an investigational, brain-penetrant HER2 inhibitor being developed for cancers driven by HER2, including cancers that may spread to the brain. Iambic’s broader work focuses on advancing drug candidates generated through its technology platform.
Featured Articles
- Five stocks we like better than Iambic Therapeutics
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
Receive News & Ratings for Iambic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iambic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
